Physician profile
Rachel Suk
NPI 1932829637
$2,373.76
in general payments reported to CMS, 2019-2025
16 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $785 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $419.60 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $386.19 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $312.87 | 2024-2025 | Auvelity |
| Corium, LLC | $226.63 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $164.81 | 2024-2025 | Qelbree |
| Abbvie INC. | $129.70 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.26 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $122.85 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $119.03 | 2024-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $95.62 | 2024-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $84.94 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $75.46 | 2024-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $57.69 | 2024-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $20.69 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $15.70 | 2024 | Relexxii |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $14.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Suk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.